Amid the push for easier administration in immunotherapy, Ambrx/Ambrx?—the program described here—reported early safety and activity for subcutaneous tarlatamab in extensive-stage small cell lung cancer. New phase 1b DeLLphi-308 results (and related updates) suggest a potentially more patient-friendly route while the field weighs durability and sequencing questions.